Key facts
- This page summarizes R. Jacob Vogelstein's Form 4 filing for Iambic Therapeutics, Inc. (IAM).
- 8 reported transactions and 5 derivative rows are listed below.
- Accepted by SEC: 19 Oct 2026, 19:53.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Additional SEC filing notes
Footnote F1
Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.
Footnote F2
Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.
Footnote F3
Each share of Series B-3 Convertible Preferred Stock automatically converted into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.
Footnote F4
The shares are held of record by Catalio Nexus Fund III, LP, or Catalio Nexus. Catalio Capital Management, LP, or Catalio Capital Mgmt, a registered investment advisor, is the investment manager for Catalio Nexus. As a managing partner of Catalio Capital Mgmt, the reporting person shares voting and dispositive power with respect to the shares held by Catalio Nexus. The reporting person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any.
Footnote F5
Each share of Series B-4 Convertible Preferred Stock automatically converted into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.
Footnote F6
The shares are held of record by Catalio Access Fund VIII, LLC, or Catalio Access. Catalio Capital Mgmt provides investment management services for Catalio Access. As a managing partner of Catalio Capital Mgmt, the reporting person shares voting and dispositive power with respect to the shares held by Catalio Access.The reporting person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any.
Footnote F7
The conversion price was equal to 85% of the Issuer's initial public offering price of $16.00 per share (reflecting a 15% discount).
Footnote F8
The shares are held of record by Catalio BH SPV, LLC, or Catalio SPV. Catalio Capital Mgmt is the investment manager for Catalio SPV. As a managing partner of Catalio Capital Mgmt, the reporting person shares voting and dispositive power with respect to the shares held by Catalio SPV. The reporting person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any.